Search IBRX
ImmunityBio, Inc.
Nasdaq · CIK 1326110
Last close10.28
Daily change+1.01 (10.83%)
10 Years gain+35.51%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
IBRX · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
50.7Momentum
100.0Acceleration
100.0Confidence
71.0Annual Revenue13
Quarterly Revenue55
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality8.2 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 1262.7981 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 23.0798%.
Key Metrics
Revenue Growth TTM549.23%OK
Revenue CAGR 3Y678.62%OK
Gross Margin99.45%OK
Operating Margin-167.87%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y53.52%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y23.08%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $113.29M | $112.54M | -$256.03M | -$304.94M | -$308.78M | 99.34% | -226% | -272.56% | n/a | 919.86M |
| 2025 FY Dec 31, 2024 | $14.75M | $14.75M | -$344.18M | -$391.24M | -$398.12M | 100% | -2,334.23% | -2,700.06% | n/a | 700.44M |
| 2025 FY Dec 31, 2023 | $622,000.00 | $622,000.00 | -$362.25M | -$366.76M | -$397.34M | 100% | -58,239.55% | -63,881.19% | n/a | 508.64M |
| 2024 FY Dec 31, 2022 | $240,000.00 | $240,000.00 | -$351.30M | -$337.51M | -$415.67M | 100% | -146,374.17% | -173,196.25% | n/a | 399.9M |
| 2023 FY Dec 31, 2021 | $934,000.00 | $934,000.00 | -$330.28M | -$274.42M | -$307.98M | 100% | -35,361.88% | -32,974.52% | n/a | 389.23M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $153.93M | sum latest 4 fiscal quarters Revenue | OK | 0001326110-26-000079, 0001326110-25-000139 |
| Revenue Growth TTM | 549.23% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001326110-26-000079, 0001326110-25-000139 |
| Revenue CAGR 3Y | 678.62% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001326110-26-000030 |
| Revenue CAGR 5Y | 184.76% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001326110-26-000030 |
| Gross Profit CAGR 3Y | 676.89% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001326110-26-000030 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001326110-26-000079, 0001326110-25-000139 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 99.45% | Gross Profit / Revenue | OK | 0001326110-26-000079, 0001326110-25-000139 |
| Operating Margin | -167.87% | Operating Income / Revenue | OK | 0001326110-26-000079, 0001326110-25-000139 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001326110-26-000079 |
| Current Ratio | 5.72x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.15 | Revenue / Diluted Shares | OK | 0001326110-26-000079, 0001326110-25-000139 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001326110-26-000030 |